Abiopharma

🔍 Busch Matthew C. (Executive)

Company: AMGEN INC (AMGN)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 455 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,435.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50 shares of Common Stock at $329.59 per share (Direct)
  Date: 2026-05-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 4,385.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,969 shares of Nqso (Right to Buy) at $329.59 per share (Derivative)
  Date: 2026-05-05 | Code: A | Expires: 2036-05-05 | Exercise: 2027-05-05 | equity_swap_involved: 0 | shares_owned_after: 2,969.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
• F2: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
• F3: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.